Research and Markets: Analyze How the Asthma and COPD Therapy Spiriva Will Act as the Key Driver of Boehringer Ingelheim's Commercial Performance out to 2012

Business Wire,  July 9, 2008  

• E-mail
• Print
• Link

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/528cb4/boehringer_ingelhe) has announced the addition of the "Boehringer Ingelheim GmbH: PharmaVitae Profile" company profile to their offering.

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Key reasons to purchase this title

- Benchmark Boehringer Ingelheim's performance against key rivals in the ethical pharmaceutical sector

- Analyze how the asthma and COPD therapy Spiriva will act as the key driver of Boehringer Ingelheim's commercial performance out to 2012

- Assess Boehringer Ingelheim's narrow therapeutic focus and the potential barrier to sales growth that this will provide

Key Chapters Covered:

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 CORPORATE HISTORY

CHAPTER 3 HISTORICAL PERFORMANCE

CHAPTER 4 FORECAST PERFORMANCE

CHAPTER 5 KEY PRODUCTS AND COMPETITORS

CHAPTER 6 APPENDIX

List of Tables

List of Figures

Companies Mentioned:

- Abbott Laboratories

- Astellas Pharma

- AstraZeneca PLC

- Boehringer Ingelheim GmbH

- Daiichi Sankyo, Ltd.

- Eli Lilly and Company

- GlaxoSmithKline Plc

- IMS Health

- Johnson & Johnson

- Merck & Co., Inc.

- Novartis AG

- Pfizer Inc

For more information visit http://www.researchandmarkets.com/research/528cb4/boehringer_ingelhe

Source: Datamonitor

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning